Cargando…
Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity
AIM: Multiple drug intolerance syndrome (MDIS) is a unique clinical entity distinct from other drug hypersensitivity syndromes. The aim of this review was to critically appraise the various aspects of MDIS. METHODS: A review was conducted to search for the causes, mechanism, clinical features, and m...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011677/ https://www.ncbi.nlm.nih.gov/pubmed/30417793 http://dx.doi.org/10.2174/1574884713666181112125714 |
_version_ | 1783496109788758016 |
---|---|
author | Behera, Sapan K. Das, Saibal Chengappa, Kavadichanda G. Xavier, Alphienes S. Selvarajan, Sandhiya |
author_facet | Behera, Sapan K. Das, Saibal Chengappa, Kavadichanda G. Xavier, Alphienes S. Selvarajan, Sandhiya |
author_sort | Behera, Sapan K. |
collection | PubMed |
description | AIM: Multiple drug intolerance syndrome (MDIS) is a unique clinical entity distinct from other drug hypersensitivity syndromes. The aim of this review was to critically appraise the various aspects of MDIS. METHODS: A review was conducted to search for the causes, mechanism, clinical features, and management of MDIS. RESULTS: The most common cause of MDIS is antibiotics followed by non-steroidal anti-inflammatory drugs (NSAIDs). Although some non-specific immunological mechanisms are involved, the immunological tests for MDIS are negative. Rashes, gastrointestinal reflux, headache, cough, muscle ache, fever, dermatitis, hypertension, and psychiatric symptoms are the usual manifestations. Treatment is mostly symptomatic with the withdrawal of the offending drug. Drug re-challenges and desensitization may be required for the management of this syndrome. CONCLUSION: MDIS occurs by a nonimmune mechanism which requires a prompt withdrawal of the offending drug(s), and in some cases may require drug re-challenge and desensitization. |
format | Online Article Text |
id | pubmed-7011677 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Bentham Science Publishers |
record_format | MEDLINE/PubMed |
spelling | pubmed-70116772020-03-06 Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity Behera, Sapan K. Das, Saibal Chengappa, Kavadichanda G. Xavier, Alphienes S. Selvarajan, Sandhiya Curr Clin Pharmacol Article AIM: Multiple drug intolerance syndrome (MDIS) is a unique clinical entity distinct from other drug hypersensitivity syndromes. The aim of this review was to critically appraise the various aspects of MDIS. METHODS: A review was conducted to search for the causes, mechanism, clinical features, and management of MDIS. RESULTS: The most common cause of MDIS is antibiotics followed by non-steroidal anti-inflammatory drugs (NSAIDs). Although some non-specific immunological mechanisms are involved, the immunological tests for MDIS are negative. Rashes, gastrointestinal reflux, headache, cough, muscle ache, fever, dermatitis, hypertension, and psychiatric symptoms are the usual manifestations. Treatment is mostly symptomatic with the withdrawal of the offending drug. Drug re-challenges and desensitization may be required for the management of this syndrome. CONCLUSION: MDIS occurs by a nonimmune mechanism which requires a prompt withdrawal of the offending drug(s), and in some cases may require drug re-challenge and desensitization. Bentham Science Publishers 2019-12 2019-12 /pmc/articles/PMC7011677/ /pubmed/30417793 http://dx.doi.org/10.2174/1574884713666181112125714 Text en © 2019 Bentham Science Publishers https://creativecommons.org/licenses/by-nc/4.0/legalcode This is an open access article licensed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International Public License (CC BY-NC 4.0) (https://creativecommons.org/licenses/by-nc/4.0/legalcode), which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited. |
spellingShingle | Article Behera, Sapan K. Das, Saibal Chengappa, Kavadichanda G. Xavier, Alphienes S. Selvarajan, Sandhiya Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity |
title | Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity |
title_full | Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity |
title_fullStr | Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity |
title_full_unstemmed | Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity |
title_short | Multiple Drug Intolerance Syndrome: An Underreported Distinct Clinical Entity |
title_sort | multiple drug intolerance syndrome: an underreported distinct clinical entity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011677/ https://www.ncbi.nlm.nih.gov/pubmed/30417793 http://dx.doi.org/10.2174/1574884713666181112125714 |
work_keys_str_mv | AT beherasapank multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity AT dassaibal multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity AT chengappakavadichandag multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity AT xavieralphieness multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity AT selvarajansandhiya multipledrugintolerancesyndromeanunderreporteddistinctclinicalentity |